
    the study was terminated due to low enrollment.
  
['primary myelofibrosis']
['ruxolitinib']

        Inclusion Criteria:

          -  Confirmed diagnosis of PMF, PPV MF or PET-MF, irrespective of JAK2 mutational status
             according to the 2008 revised International Standard Criteria

          -  Peripheral blast count < 10%

          -  Requires therapy for MF in the opinion of the investigator

          -  Received prior monotherapy treatment with ruxolitinib for at least 12 consecutive
             weeks and experienced treatment interruption because of lossof response or adverse
             event

          -  Patients adhering to the Screening phase assessments and undergoing a a
             ruxolitinib-free washout period of a minimum of 1 week and a maximum of 8 weeks

          -  ECOG performance status 0, 1, 2, or 3

          -  Adequate bone marrow function

          -  Written informed consent

        Exclusion Criteria:

          -  Patients not initially responding (primary resistance) to ruxolitinib therapy

          -  Patients who underwent a splenectomy or spleen radiation

          -  Patients currently scheduled for bone marrow transplant

          -  Patients who have discontinued ruxolitinib < 14 days prior to screening

          -  Patients who are not able to receive a starting dose of ruxolitinib of at least 15 mg
             total daily dose

          -  Leukemic transformation

          -  Inadequate renal function

          -  Presence of clinically meaningful active bacterial, fungal, parasitic or viral
             infection which requires therapy

          -  Previous history of Progressive Multifocal Leuko-encephalopathy (PML)

          -  Clinically significant cardiac disease or significant concurrent medical condition
      